Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Sues Cephalon For Anticompetitive Side Deals In Reverse Settlements

Executive Summary

The Federal Trade Commission is once again challenging reverse settlements between a brand name company and its would-be generic competitors. This time around, the agency is focusing on side deals tacked onto the settlements, contending they constitute unfair competition

Related Content

Teva Pay-For-Delay Plausible; Judge Finds Payments Exceed Litigation Costs
Cephalon Loses Market Exclusivity On Provigil To Its Own Parent Company
Patent Round-Up: Sanofi Settles Eloxatin Suits; Lilly Continues Gemzar Fight
FTC Chairman To Be Jon Leibowitz: Will Reverse Payments Get More Scrutiny?
Antitrust Enforcement Under Obama: Pfizer-Wyeth Offers An Early Test
Pfizer Settlement With Ranbaxy Delays Generic Lipitor Entry
Brand, Generic Companies Excluding Side Deals In Reverse Settlements
AstraZeneca Settles Nexium Case With Ranbaxy; Can It Delay Other Generics?
FDA Approves Cephalon’s CLL Therapy Treanda With Broad Label
Barr Inks Second Settlement Over Its Delay In Launching Generic Ovcon



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts